Skip to main
ACTU

ACTU Stock Forecast & Price Target

ACTU Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Actuate Therapeutics Inc. demonstrates a promising outlook due to the strong efficacy displayed by its lead compound, elraglusib, which significantly improved the 12-month overall survival rate from 22.3% to 44.4% in combination with gemcitabine/nab-paclitaxel, thus indicating a highly favorable treatment response in difficult-to-treat cancers. The potential for expedited market entry, should a positive decision on a comprehensive market application (CMA) be granted, could enhance revenue projections by reducing the time to commercialization for elraglusib by 18 months. Furthermore, Actuate's strategy to seek non-dilutive funding through grants and investigator-initiated trials could mitigate financial risks associated with advancing its clinical programs, positioning the company for sustained growth as it expands its development pipeline into additional indications.

Bears say

Actuate Therapeutics Inc faces a negative outlook primarily due to the overall market sentiment surrounding oncology drugs, despite some positive decisions for similar therapies. The company is experiencing a reduction in projected financial performance, as indicated by a lowered price target, suggesting a reevaluation of the anticipated success and potential revenue from elraglusib. Additionally, while elraglusib’s data may appear strong, it is critical to note that the competitive landscape includes therapies that have also received positive evaluations, potentially diluting Actuate's market position.

ACTU has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Actuate Therapeutics Inc (ACTU) Forecast

Analysts have given ACTU a Strong Buy based on their latest research and market trends.

According to 2 analysts, ACTU has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Actuate Therapeutics Inc (ACTU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.